BRPI0511206A - composição farmacêutica anidra e uso de um ungüento oleaginoso - Google Patents

composição farmacêutica anidra e uso de um ungüento oleaginoso

Info

Publication number
BRPI0511206A
BRPI0511206A BRPI0511206-0A BRPI0511206A BRPI0511206A BR PI0511206 A BRPI0511206 A BR PI0511206A BR PI0511206 A BRPI0511206 A BR PI0511206A BR PI0511206 A BRPI0511206 A BR PI0511206A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
anhydrous pharmaceutical
oil ointment
anhydrous
ointment
Prior art date
Application number
BRPI0511206-0A
Other languages
English (en)
Inventor
Leslie Zanutto
Sandrine Orsoni
Nathalie Barthez
Original Assignee
Galderma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Sa filed Critical Galderma Sa
Publication of BRPI0511206A publication Critical patent/BRPI0511206A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

COMPOSIçãO FARMACêUTICA ANIDRA E USO DE UM UNGüENTO OLEAGINOSO A presente invenção trata de uma composição farmacêutica anidra destinada ao tratamento da psoríase caracterizada pelo lato de compreender um ungüento oleaginoso e, como princípios ativos, calcitriol e 17-propionato de clobetasol, sendo que os referidos ativos estão em forma solubilizada na referida composição.
BRPI0511206-0A 2004-06-17 2005-06-15 composição farmacêutica anidra e uso de um ungüento oleaginoso BRPI0511206A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0406609A FR2871694B1 (fr) 2004-06-17 2004-06-17 Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises
PCT/FR2005/001493 WO2006005842A1 (fr) 2004-06-17 2005-06-15 Composition pharmaceutique comprenant un onguent oleagineux et deux principes actifs solubilises.

Publications (1)

Publication Number Publication Date
BRPI0511206A true BRPI0511206A (pt) 2007-11-27

Family

ID=34946515

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0511206-0A BRPI0511206A (pt) 2004-06-17 2005-06-15 composição farmacêutica anidra e uso de um ungüento oleaginoso

Country Status (14)

Country Link
US (1) US20050281848A1 (pt)
EP (1) EP1758588B1 (pt)
JP (1) JP2008502661A (pt)
CN (1) CN101090725A (pt)
AT (1) ATE489098T1 (pt)
AU (1) AU2005261569A1 (pt)
BR (1) BRPI0511206A (pt)
CA (1) CA2567680A1 (pt)
DE (1) DE602005024959D1 (pt)
ES (1) ES2360469T3 (pt)
FR (1) FR2871694B1 (pt)
MX (1) MXPA06014407A (pt)
RU (1) RU2007101516A (pt)
WO (1) WO2006005842A1 (pt)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2885527B1 (fr) * 2005-05-16 2007-06-29 Galderma Res & Dev Composition pharmaceutique comprenant un onguent oleagineux et de la vitamine d ou ses derives a l'etat solubilise
JP2010502624A (ja) * 2006-08-29 2010-01-28 テバ ファーマシューティカル インダストリーズ リミティド 低ｐＨ親和性を有するコルチコステロイド化合物及びビタミンＤ含有化合物を含む安定な薬理活性組成物
FR2909284B1 (fr) * 2006-11-30 2012-09-21 Galderma Sa Nouvelles compositions sous forme d'onguent sans vaseline comprenant un derive de vitamine d et eventuellement un anti-inflammatoire steroidien
FR2912655A1 (fr) * 2007-02-15 2008-08-22 Galderma Sa Produit de soin cutane a double compartiment comprenant du calcitriol et du propionate de clobetasol, et son utilisation
EP1970048A1 (en) * 2007-03-15 2008-09-17 Drug Delivery Solutions Limited Polyaphron topical composition with vitamin D
US10265265B2 (en) 2007-03-15 2019-04-23 Drug Delivery Solutions Limited Topical composition
EP2008651A1 (en) 2007-06-26 2008-12-31 Drug Delivery Solutions Limited A bioerodible patch
US20120004200A1 (en) * 2008-12-23 2012-01-05 Galderma S.A. Topical pharmaceutical composition containing a water-sensitive active principle
EP2515865B1 (en) * 2009-12-22 2016-12-14 Leo Pharma A/S Cutaneous composition comprising vitamin d analogue and a mixture of solvent and surfactants
AU2010335656B2 (en) * 2009-12-22 2015-05-07 Leo Pharma A/S Pharmaceutical composition comprising solvent mixture and a vitamin D derivative or analogue
WO2012123515A1 (en) 2011-03-14 2012-09-20 Drug Delivery Solutions Limited An ophthalmic composition
CN104666312B (zh) * 2015-02-12 2017-11-07 重庆华邦制药有限公司 含有卡泊三醇和二丙酸倍他米松的制剂
CN108969527B (zh) * 2017-05-31 2021-05-11 上海通用药业股份有限公司 一种药物制剂及其制备方法和用途
EP3542788A1 (en) 2018-03-19 2019-09-25 MC2 Therapeutics Limited Topical composition comprising calcipotriol and betamethasone dipropionate

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1272953A (en) * 1984-10-08 1990-08-21 Yuji Makino Pharmaceutical composition for external use containing active-type vitamin d.sub.3
US5185150A (en) * 1990-08-24 1993-02-09 Wisconsin Alumni Research Fdn. Cosmetic compositions containing 19-nor-vitamin D compounds
NZ515142A (en) * 1999-04-23 2004-01-30 Leo Pharm Prod Ltd Pharmaceutical composition
AU9163701A (en) * 2000-10-27 2002-05-06 Leo Pharma As Topical composition containing at least one vitamin D or one vitamin D analogue and at least one corticosteroid
FR2848454B1 (fr) * 2002-12-17 2007-03-30 Galderma Res & Dev Composition pharmaceutique comprenant une association de calcitriol et d'un corticosteroide
KR20050085787A (ko) * 2002-12-17 2005-08-29 갈데르마 소시에떼아노님 칼시트리올 및 클로베타솔 프로피오네이트의 배합물을함유하는 약학 조성물
US7582307B2 (en) * 2003-11-26 2009-09-01 Harmony Labs, Inc. Dermatological composition

Also Published As

Publication number Publication date
EP1758588B1 (fr) 2010-11-24
MXPA06014407A (es) 2007-02-19
WO2006005842A1 (fr) 2006-01-19
AU2005261569A1 (en) 2006-01-19
CN101090725A (zh) 2007-12-19
FR2871694A1 (fr) 2005-12-23
JP2008502661A (ja) 2008-01-31
ES2360469T3 (es) 2011-06-06
DE602005024959D1 (de) 2011-01-05
RU2007101516A (ru) 2008-07-27
CA2567680A1 (fr) 2006-01-19
US20050281848A1 (en) 2005-12-22
EP1758588A1 (fr) 2007-03-07
FR2871694B1 (fr) 2008-07-04
ATE489098T1 (de) 2010-12-15

Similar Documents

Publication Publication Date Title
BRPI0511206A (pt) composição farmacêutica anidra e uso de um ungüento oleaginoso
FR21C1064I2 (fr) Compositions et procedes de traitement de troubles impliquant une proliferation cellulaire
CL2009000393A1 (es) Composición farmaceutica que comprende a) un agente farmaceutico activable, b) un agente activo plasmonico; util para el tratamiento de trastornos de proliferación celular.
BR112022003335A2 (pt) Conjugados de il-2 e métodos de uso para tratar doenças autoimunes
EA200870292A1 (ru) Соединения на основе имидазола, композиции, содержащие их, и способы их применения
EA200700118A1 (ru) Амидосоединения и их применение в качестве лекарственных средств
MXPA03010487A (es) Derivados de diarilurea utiles como agentes antiinflamatorios.
BRPI0411699A (pt) compostos para uso como substáncia terapeuticamente ativa; método para o tratamento e/ou profilaxia de doenças que estão associadas à modulação de receptores cb1 e uso destes compostos
EP1575509A4 (en) EPHA2 AGONISTIC MONOCLONAL ANTIBODIES AND METHOD OF USE THEREOF
BR112014000178A2 (pt) composições tópicas
BRPI0620436A8 (pt) compostos miméticos de lisina modificados, composição farmacêutica e uso
WO2007011606A3 (en) USE OF HMGBl ANTAGONISTS FOR THE TREATMENT OF INFLAMMATORY SKIN CONDITIONS
TW200714590A (en) Heterocyclic inhibitors of MEK and methods of use thereof
MY158428A (en) Topical composition for the treatment of actinic keratosis
CL2012002887A1 (es) Combinación farmacéutica que comprende compuestos derivados de 2,3-dihidroimidazo[1,2-c]quinazolina sustituida, compuestos derivados de n-(2-arilamino)arilsulfonamida y opcionalmente otros agentes farmacéuticos adicionales; kit faramacéutico; método de tratamiento; y su uso para el tratamiento o la profilaxis del cáncer.
CY1109507T1 (el) Φαρμακευτικη συνθεση η οποια περιλαμβανει ενα ελαστομερες οργανοπολυσιλοξανιο και μια διαλυτοποιημενη δραστικη ουσια
CY1113424T1 (el) Μεθοδος αντιμετωπισης του καρκινου ή/και παθησεις με κυτταρικη υπερπλασια και παραγοντες που στοχευουν τον αναβολισμο υαλουρονανης για τον ιδιο σκοπο
CL2011000722A1 (es) Composicion farmaceutica en forma de unguento estable al almacenamiento, que comprende: a) un compuesto de vitamina d, b) un corticosteroide y c) un compuesto alquilamino sustituido, en un vehiculo de petrolato que opcionalmente contiene aceite mineral, tocoferol o una combinacion de ellos; uso en tratamiento de la psoriasis.
BRPI0617655A2 (pt) composto ou um sal farmaceuticamente aceitável do mesmo, ou um isômero óptico do mesmo, uso de um composto, e, formulação farmacêutica
BRPI0514723A (pt) composições contendo componentes de agonista alfa-2-adrenérgico
AR023546A1 (es) Disulfuros ciclicos de pirrolidincarbonilamina
ATE374614T1 (de) Pharmazeutische zusammensetzung enthaltend calcitriol und clobetasol propionate
BRPI0511398A (pt) composição farmacêutica anidra para o tratamento da psorìase e uso de um agente siliconado
UY29069A1 (es) Uso de compuestos tpo miméticos y composiciones farmacéuticas para el tratamiento de la anemia
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]